Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1880 - AFR as a prognostic biomarker to predict clinical outcome of NSCLC individuals (34P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Shu-Qi Li

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

S. Li1, Y. Jiang1, X. Wang2, H. Ying2

Author affiliations

  • 1 Deparment Of Clinical Laboratory, 2nd Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 2 Jiangxi Province Key Laboratory Of Laboratory Medicine, 2nd Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
More

Resources

Abstract 1880

Background

Chronic inflammation is one of the critical causes to promote initiation and metastasis of solid malignancies including lung cancer. Inflammatory biomarkers, fibrinogen (Fib) and albumin (Alb), are significantly correlated with survival of other cancer. Here, we aim to investigate the prognostic roles of Alb to Fib ratio (AFR), Fib and Alb in lung cancer and to establish a novel effective nomogram combined with AFR.

Methods

412 lung cancer (LC) patients diagnosed between Feb 2005 and Dec 2014 were recruited in this retrospective study. the survival data were obtained by 3 years’ following-up. The prognostic roles of AFR, Fib, Alb, NLR, PLR and MLR were identified by X-tile software, Kaplan-Meier curve, Cox regression model and time-dependent ROC.

Results

In our study, the optimal cut-off values of AFR, Fib, Alb, NLR, PLR and MLR were 7.8, 3.3 mg/dL, 39.0 g/L, 2.7, 144.0 and 0.2, respectively. Low AFR (adjusted HR = 1.820, 95%CI=1.250-2.652 for LC; adjusted HR = 2.308, 95%CI=1.478-3.606 for NSCLC), high Fib (adjusted HR = 1.575, 95%CI=1.108-2.238 for LC; adjusted HR = 1.892, 95%CI=1.257-2.846 for NSCLC), low Alb (adjusted HR = 1.524, 95%CI=1.157-2.006 for LC; adjusted HR = 1.811, 95%CI=1.326-2.474 for NSCLC) were significantly associated with increased risk of death for LC patients, especially for NSCLC patients in all stages; high NLR was obviously associated with poor survival in LC individuals (adjusted HR = 1.405, 95%CI=1.066-1.852), particularly NSCLC (adjusted HR = 1.552, 95%CI=1.129-2.133) and TNM IV stage (adjusted HR = 1.92, 95%CI=1.201-3.071) patients, and high PLR (adjusted HR = 1.391, 95%CI=1.064-1.820 for LC; adjusted HR = 2.186, 95%CI=1.186-4.033 for TNM IV stage) was significantly increased risk of death for advanced stage LC patients. Moreover, the area under curves (AUCs) within AFR, Fib, NLR were higher than that within Alb and PLR for prediction of survival of NSCLC patients; c-index of predicted nomogram for NSCLC including AFR was higher than that without these additional parameters (c-index= 0.731 vs.0.719).

Conclusions

Our findings demonstrated that circulating pre-treatment AFR was a promising prognostic biomarker to improve the predicted efficacy of nomogram for NSCLC.

Clinical trial identification

Legal entity responsible for the study

The Ethical Committees of the two hospitals The second Affiliated Hospital of Nanchang University (Jiangxi, China) and The first Affiliated Hospital of Nanchang University (Jiangxi, China).

Funding

The National Natural Science Foundation of China under Grant (No. 81360083, No. 81271912 and No. 81560033); and 2016 Jiangxi Province Postgraduate Innovation Special Fund under Grant (No. YC2016-S057).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings